Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

por Chantkran, Wittawat, Hsieh, Ya-Ching, Zheleva, Daniella, Frame, Sheelagh, Wheadon, Helen, Copland, Mhairi
Publicado 2021

Correction to: Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML

por Chantkran, Wittawat, Hsieh, Ya-Ching, Zheleva, Daniella, Frame, Sheelagh, Wheadon, Helen, Copland, Mhairi
Publicado 2021

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer

por Frame, Sheelagh, Saladino, Chiara, MacKay, Craig, Atrash, Butrus, Sheldrake, Peter, McDonald, Edward, Clarke, Paul A., Workman, Paul, Blake, David, Zheleva, Daniella
Publicado 2020

Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial

por Siebert, Stefan, Pratt, Arthur G., Stocken, Deborah D., Morton, Miranda, Cranston, Amy, Cole, Michael, Frame, Sheelagh, Buckley, Christopher D., Ng, Wan-Fai, Filer, Andrew, McInnes, Iain B., Isaacs, John D.
Publicado 2020

Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial

por Pratt, Arthur G, Siebert, Stefan, Cole, Michael, Stocken, Deborah D, Yap, Christina, Kelly, Stephen, Shaikh, Muddassir, Cranston, Amy, Morton, Miranda, Walker, Jenn, Frame, Sheelagh, Ng, Wan-Fai, Buckley, Christopher D, McInnes, Iain B, Filer, Andrew, Isaacs, John D
Publicado 2021

Data Sharing Reveals Complexity in the Westward Spread of Domestic Animals across Neolithic Turkey

por Arbuckle, Benjamin S., Kansa, Sarah Whitcher, Kansa, Eric, Orton, David, Çakırlar, Canan, Gourichon, Lionel, Atici, Levent, Galik, Alfred, Marciniak, Arkadiusz, Mulville, Jacqui, Buitenhuis, Hijlke, Carruthers, Denise, De Cupere, Bea, Demirergi, Arzu, Frame, Sheelagh, Helmer, Daniel, Martin, Louise, Peters, Joris, Pöllath, Nadja, Pawłowska, Kamilla, Russell, Nerissa, Twiss, Katheryn, Würtenberger, Doris
Publicado 2014